Malaysia Pharma and Healthcare Sector Report 2025-2026

Malaysia's pharmaceutical and healthcare sector is among the most advanced in Southeast Asia. Malaysia's healthcare system is divided into a taxpayer-funded and government-run system and a fee-paying private sector. The public system, overseen by the Ministry of Health (MoH), is the foundation of Malaysian healthcare. It offers heavily subsidised healthcare to Malaysian citizens. In the public healthcare system, patients are granted access to higher-tier services only after consultation with general practitioners or outpatient departments, demonstrating that their treatment requires more specialised skills or advanced equipment. Private healthcare providers allow fee-paying patients to consult with specialists directly, which expedites the treatment process but also contributes to instances of superfluous testing and treatment.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Malaysia. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Malaysia
• Crystallise the forces both driving and restraining this sector in Malaysia
• Ascertain Malaysia’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Malaysia.
• Build a clear picture of trends, output and consumption for specific sub-sectors